TICKERNOMICS Sign up
Last Update: 2024-12-27 15:28:45
BIOVIE INC. ( BIVI ) https://bioviepharma.com
2.25USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-81.48%
BIVI
SPY
32.66%
-95.00%
BIVI
SPY
108.59%
-93.57%
BIVI
SPY
302.52%
-99.38%
BIVI
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
12.16
-5.37
1.18
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.48
0.00
0.86
-356.82
0.00
0.26
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
8.368
-54.30
-88.55
1.10
Other Earnings and Cash Flow Stats:
BIOVIE INC. ( BIVI ) Net Income TTM ($MM) is -25.56
BIOVIE INC. ( BIVI ) Operating Income TTM ($MM) is -25.43
BIOVIE INC. ( BIVI ) Owners' Earnings Annual ($MM) is 0.00
BIOVIE INC. ( BIVI ) Current Price to Owners' Earnings ratio is 0.00
BIOVIE INC. ( BIVI ) EBITDA TTM ($MM) is -25.20
BIOVIE INC. ( BIVI ) EBITDA Margin is 0.00%
Capital Allocation:
BIOVIE INC. ( BIVI ) has paid 0.00 dividends per share and bought back -2.724079 million shares in the past 12 months
BIOVIE INC. ( BIVI ) has reduced its debt by 9.931787 million USD in the last 12 months
Capital Structure:
BIOVIE INC. ( BIVI ) Interest-bearing Debt ($MM) as of last quarter is 2
BIOVIE INC. ( BIVI ) Annual Working Capital Investments ($MM) are -4
BIOVIE INC. ( BIVI ) Book Value ($MM) as of last quarter is 14
BIOVIE INC. ( BIVI ) Debt/Capital as of last quarter is 17%
Other Balance Sheet Stats:
BIOVIE INC. ( BIVI ) has 20 million in cash on hand as of last quarter
BIOVIE INC. ( BIVI ) has 6 million of liabilities due within 12 months, and long term debt 7 as of last quarter
BIOVIE INC. ( BIVI ) has 6 common shares outstanding as of last quarter
BIOVIE INC. ( BIVI ) has 0 million USD of preferred stock value
Academic Scores:
BIOVIE INC. ( BIVI ) Altman Z-Score is -23.78 as of last quarter
BIOVIE INC. ( BIVI ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
BIOVIE INC. ( BIVI ) largest shareholder is JONES FINANCIAL COMPANIES LLLP owning 10 shares at 0.00 ($MM) value
Cuong V Do(an insider) Bought 10000 shares of BIOVIE INC. ( BIVI ) for the amount of $17800.00 on 2023-11-30
13.69% of BIOVIE INC. ( BIVI ) is held by insiders, and 9.99% is held by institutions
BIOVIE INC. ( BIVI ) went public on 2014-05-05
Other BIOVIE INC. ( BIVI ) financial metrics:
FCF:-19.35
Unlevered Free Cash Flow:0.00
EPS:-2.60
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-118.06
Beta:1.10
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BIOVIE INC. ( BIVI ) :
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.